登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600971 证券简称：恒源煤电 公告编号：2026-012 安徽恒源煤电股份有限公司 关于以集中竞价交易方式回购公司股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币20,000万元，不高于人民币25,000万元。 ● 回购股份资金来源：公司自有资金 ● 回购股份用途：回购股份用于转换公司发行的可转换公司债券。若公司未能在股份回购实施完成后三 年内转换完毕，未转换股份将依法履行相关程序后予以注销。 ● 回购股份价格：不超过人民币 9.55元/股。该价格不高于公司董事会通过回购股份决议前 30 个交易日 公司股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式 1.本次回购期限内，存在公司股票价格持续超出回购方案披露的价格上限，导致本次回购方案无法顺利 实施的风险； 2.若发生对公司股票交易价格产生重大影响的事项，或公司生产经营、财务状况、外部客观情况发生重 大变化，或其他导致公司董事会决定终 ...

Group 1 - The company held its 45th meeting of the 8th Board of Directors on February 9, 2026, via communication methods [3][5] - All 9 directors participated in the voting process, with unanimous approval for the resolutions [4][7] - The meeting was chaired by acting chairwoman Zhang Li, and senior management attended [5] Group 2 - The board approved the nomination of Ms. Li Xiaoguang as an independent director candidate, who meets the qualifications set by relevant regulations [6] - Upon approval by the shareholders' meeting, Ms. Li will also serve as the chair of the Compensation and Assessment Committee and a member of the Nomination Committee [6] - The independent director candidate's qualifications will be subject to review by the Shenzhen Stock Exchange before being submitted for shareholder approval [6] Group 3 - Ms. Li Xiaoguang has a distinguished background, including roles in arbitration and legal advisory, and has received multiple accolades for her contributions [10] - She does not hold any shares in the company and has no relationships with major shareholders or other board members [11] - Ms. Li's qualifications comply with the requirements of the Company Law and relevant regulations [11]

Core Viewpoint - The company, Hubei Chutian Intelligent Transportation Co., Ltd., has approved a resolution regarding the transfer of equity investment fund shares and the extension of the investment period for its wholly-owned subsidiary, Hubei Chutian Expressway Investment Co., Ltd. [1][5] Summary by Sections 1. Resolution Details - The board of directors held a meeting on February 9, 2026, and unanimously approved the proposal for the transfer of 29.85% of shares in the Hubei Jiaotou Zhongjin Ruizhi Venture Capital Fund Partnership to Hubei Provincial Expressway Development Fund Partnership for a price of 216.4015 million yuan [1][7][8] - The investment period for the fund will be extended by 2 years until November 13, 2028, with the fund's duration extended to November 13, 2031 [2][20] 2. Related Transactions - The transaction constitutes a related party transaction as the transferring party, Hubei Jiaotou Investment Co., Ltd., is a wholly-owned subsidiary of the company's controlling shareholder, Hubei Jiaotou Group [7][8] - In the past 12 months, the company has engaged in 4 related transactions with the same related party, totaling 345 million yuan, and this transaction does not constitute a major asset restructuring [7][9] 3. Fund and Investment Overview - The Hubei Jiaotou Zhongjin Ruizhi Fund has a total scale of 800 million yuan, with the company having contributed 20 million yuan, holding a 2.5% share [7][17] - The fund has invested in 7 projects, with 1 project exited and 6 currently active, totaling an investment of 500.02 million yuan [17][20] 4. Impact on the Company - The share transfer will not change the company's consolidated financial statements, and the extension of the fund's investment period is expected to ensure normal operations without significant adverse effects on the company's daily operations [20] - The transaction aligns with the fund's operational status and development plan, ensuring no harm to the interests of the company and its shareholders, particularly minority shareholders [20]

Group 1 - The first extraordinary general meeting of shareholders for 2026 was held on February 9, 2026, in Nanning, Guangxi [2] - The meeting was convened by the board of directors and chaired by Mr. Feng Jian, with attendance and voting procedures compliant with the Company Law and the Articles of Association [2][3] - A total of 9 directors were in office, with 8 present; independent director Mr. Deng Weihui was absent due to a work conflict [3] Group 2 - The following proposals were reviewed and approved during the meeting: 1. Proposal on the expected daily related party transactions for 2026 [4] 2. Revision of certain company systems, including the Independent Director Work System, Related Party Transaction Management System, and Fund Management System, all of which were approved [4][5] - The related party shareholder, Guangxi Beibu Gulf Investment Group Co., Ltd., abstained from voting on the related party transaction proposal [5] Group 3 - The meeting was witnessed by lawyers from Guohao Law Firm (Nanning), with a conclusion confirming that the meeting's procedures complied with legal and regulatory requirements [5]

Core Viewpoint - The company has received a drug registration certificate for Tadalafil 20mg tablets from the Ghana Food and Drug Administration, marking a significant step in its international market expansion [1][3]. Group 1: Drug Registration Details - Drug Name: TADALAFIL 20mg TABLETS - Dosage Form: Tablet - Specification: 20mg - Registration Number: FDA/GD.255-120251 - Certificate Number: FDA-GH-77157971 - Manufacturer: Jiangsu Lianhuan Pharmaceutical Co., Ltd. - Address: No. 9, Health Road, Yangzhou Biohealth Industry Park, Yangzhou, Jiangsu Province - Validity Period: Until December 31, 2030 [1]. Group 2: Market Position and Financial Impact - The company is the only Chinese enterprise holding the Tadalafil 20mg drug registration certificate in Ghana [2]. - The sales revenue for Tadalafil tablets in 2024 is projected to be 23.0793 million RMB [1]. - The registration allows for legal sales in Ghana, but the expected revenue impact on the company's overall performance is minimal due to the current lack of sales in the region [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002199 证券简称：*ST东晶 公告编号：2026010 浙江东晶电子股份有限公司 关于公司股票可能被终止上市的第二次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、浙江东晶电子股份有限公司（以下简称"公司"）于2025年3月25日在指定信息披露媒体发布了《关于 公司股票交易被实施退市风险警示暨股票停牌的公告》（公告编号：2025014），因公司2024年度经审 计的相关财务指标触及《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"）第9.3.1条 之"（一）最近一个会计年度经审计的利润总额、净利润、扣除非经常性损益后的净利润三者孰低为负 值，且扣除后的营业收入低于3亿元"规定的对股票交易实施退市风险警示的情形，公司股票交易自2025 年3月26日起被实施退市风险警示。若公司2025年度出现《股票上市规则》第9.3.12条规定的相关情形， 公司股票存在被终止上市的风险。 2、根据《股票上市规则》第9.3.6条规定，公司应当在股票交易被实施退市风险警示当年会计 ...

证券代码：688073 证券简称：毕得医药 公告编号：2026-006 上海毕得医药科技股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2026年2月9日 （二）股东会召开的地点：上海市杨浦区翔殷路999号3幢6层会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 二、议案审议情况 （一）非累积投票议案 1、议案名称：关于修订《董事、高级管理人员薪酬管理制度》的议案 审议结果：通过 表决情况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由董事长戴岚女士主持，会议采用现场投票与网络投票相结合的表决方式进行表决。本次会 议的召集、召开符合《公司法》《公司章程》《公司股东会议事规则》等法律、法规和规范性文件的规 定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事7人，出席7人； 2、 ...

Group 1 - The company announced the resignation of Deputy General Manager Xu Rongbin due to work changes, but he will continue to hold other positions within the company [2][3] - Xu Rongbin's resignation will take effect upon delivery to the board and will not affect the company's normal operations, as he has fulfilled all public commitments during his tenure [3] - The company expressed gratitude for Xu Rongbin's contributions during his time as Deputy General Manager [3] Group 2 - The company has received approval from the Shanghai Stock Exchange for a specific stock issuance project, which was also approved by the China Securities Regulatory Commission [4] - The law firm Guohao Law Firm (Shanghai) has been appointed for the stock issuance project, with a change in signing lawyers due to the departure of one lawyer for personal reasons [5][6]

证券代码：603416 证券简称：信捷电气 公告编号：2026-005 无锡信捷电气股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年2月9日 (二)股东会召开的地点：江苏省无锡市滨湖区建筑西路816号信捷大厦会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 2、董事会秘书温波飞出席；副总经理过志强、财务总监朱佳蕾列席。 二、议案审议情况 (一)非累积投票议案 1、议案名称：《关于变更募投项目部分内容的议案》 审议结果：通过 表决情况： ■ 会议由公司董事会召集，董事长、总经理李新先生主持，采取现场投票和网络投票相结合的表决方式。 会议的召集和召开符合《公司法》《上市公司股东会规则》等相关法律法规和《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688008 证券简称：澜起科技 公告编号：2026-010 澜起科技股份有限公司 关于H股挂牌并上市交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 澜起科技股份有限公司（以下简称"公司"）正在进行发行境外上市股份（H股）并在香港联合交易所有 限公司（以下简称"香港联交所"）主板挂牌上市（以下简称"本次发行上市"）的相关工作。 公司本次全球发售H股总数为65,890,000股（行使超额配售权之前），其中，香港公开发售6,589,000 股，约占全球发售总数的10%（行使超额配售权之前）；国际发售59,301,000股，约占全球发售总数的 90%（行使超额配售权之前）。根据每股H股发售价106.89港元计算，经扣除全球发售相关包销佣金、 费用及估计开支后，在超额配售权行使之前，公司将收取的全球发售所得款项净额估计约为69.05亿港 元。 经香港联交所批准，公司本次发行的65,890,000股H股股票（行使超额配售权之前）于2026年2月9日在 香港联交所 ...